Xuanzhu Biopharmaceutical’s Anaprazole Sodium Meets Primary Endpoint in Phase III Reflux Esophagitis Trial

PUBT · 2d ago
Xuanzhu Biopharmaceutical’s Anaprazole Sodium Meets Primary Endpoint in Phase III Reflux Esophagitis Trial
  • Xuanzhu Biopharmaceutical announced Oct. 21, 2026, that anaprazole sodium met its Phase III primary endpoint, demonstrating noninferiority to rabeprazole for reflux esophagitis.
  • The trial randomized 500 patients with moderate-to-severe erosive esophagitis; results were presented at UEG Week 2026 in Barcelona.
  • Week 8 healing rates in the full analysis set were 88.4% for anaprazole versus 84.6% for rabeprazole.
  • Per-protocol healing rates reached 93.9% versus 89.4%, respectively; both analyses met the prespecified noninferiority margin of -10%.
  • All treatment-related adverse events were Grade 1-2; the new drug application for reflux esophagitis has been accepted in China.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261021-12378592), on October 21, 2026, and is solely responsible for the information contained therein.